OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
Jia‐Cheng Lu, Lei‐Lei Wu, Yining Sun, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Jia‐Cheng Lu, Lei‐Lei Wu, Yining Sun, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Showing 14 citing articles:
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Minjie Fu, Jiaxu Zhao, Licheng Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1882-1897.e7
Closed Access | Times Cited: 8
Minjie Fu, Jiaxu Zhao, Licheng Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1882-1897.e7
Closed Access | Times Cited: 8
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
A Novel 167‐Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
Canghai Guan, Gao Jianjun, Xinlei Zou, et al.
Advanced Science (2025)
Open Access
Canghai Guan, Gao Jianjun, Xinlei Zou, et al.
Advanced Science (2025)
Open Access
Xin-Fu-Kang Oral Liquid Mitigates Chronic Heart Failure through NR4A1-Dependent Regulation of Endoplasmic Reticulum-Mitochondrial Crosstalk in Cardiomyocytes
Xiaohan Zhang, Xing Chang, Ruoning Chai, et al.
Phytomedicine (2025) Vol. 140, pp. 156467-156467
Closed Access
Xiaohan Zhang, Xing Chang, Ruoning Chai, et al.
Phytomedicine (2025) Vol. 140, pp. 156467-156467
Closed Access
Targeting T-cell Aging to Remodel the Aging Immune System and Revitalize Geriatric Immunotherapy
Chen Mi, Su Zhou, Jianxin Xue
Aging and Disease (2025)
Open Access
Chen Mi, Su Zhou, Jianxin Xue
Aging and Disease (2025)
Open Access
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Eléonora De Martin, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Gut (2024), pp. gutjnl-332125
Closed Access | Times Cited: 3
Eléonora De Martin, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Gut (2024), pp. gutjnl-332125
Closed Access | Times Cited: 3
Hypocrellin A against Intrahepatic Cholangiocarcinoma via Multi-Target Inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 Signaling Pathways
Bo Chen, Qiwen Chen, Mengmeng Lu, et al.
Phytomedicine (2024) Vol. 135, pp. 156022-156022
Closed Access | Times Cited: 2
Bo Chen, Qiwen Chen, Mengmeng Lu, et al.
Phytomedicine (2024) Vol. 135, pp. 156022-156022
Closed Access | Times Cited: 2
FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma
Shaoqing Liu, Jialei Weng, Manqing Cao, et al.
The Oncologist (2024) Vol. 29, Iss. 12, pp. e1734-e1747
Open Access | Times Cited: 1
Shaoqing Liu, Jialei Weng, Manqing Cao, et al.
The Oncologist (2024) Vol. 29, Iss. 12, pp. e1734-e1747
Open Access | Times Cited: 1
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer
Luohang Ni, Jianing Xu, Quanpeng Li, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 941-963
Open Access | Times Cited: 1
Luohang Ni, Jianing Xu, Quanpeng Li, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 941-963
Open Access | Times Cited: 1
Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects
Jiayi Wang, Siyan Liu, Yi Cao, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Jiayi Wang, Siyan Liu, Yi Cao, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 1
Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor‐Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P‐Selectin/PSGL1 N‐Glycosylation Blockage
Xiaojing Du, Zhuoran Qi, Sinuo Chen, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
Xiaojing Du, Zhuoran Qi, Sinuo Chen, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer
Qing Wang, Yushuai Yu, Chenxi Wang, et al.
British Journal of Cancer (2024)
Closed Access
Qing Wang, Yushuai Yu, Chenxi Wang, et al.
British Journal of Cancer (2024)
Closed Access
Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study
Liangyou Gu, Cheng Peng, Qiyang Liang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access
Liangyou Gu, Cheng Peng, Qiyang Liang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access
Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
Zhenyun Yang, Weijie Wu, Zhiwen Hu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Zhenyun Yang, Weijie Wu, Zhiwen Hu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
